Results 1 to 10 of about 3,616,916 (178)

Robert J. Shiller: Nobel Prize for 2013: Capital Market Efficiency [PDF]

open access: yesBankarstvo, 2015
In 2013 the Nobel Prize in Economic Sciences was awarded to the American economists, Eugene Fama, Lars Peter Hansen and Robert Shiller. The monetarists, Fama and Hansen, from the University of Chicago, and the Neo- Keynesian, Shiller, from the Yale University, according to the Swedish Royal Academy, won this prestigious prize for their research ...
Svetlana Pantelić
exaly   +4 more sources

Perpetual Futures for Stocks: The SpaceX Pre-IPO Market. [PDF]

open access: yesEntropy (Basel)
Robert Shiller proposed perpetual futures in 1993 to create derivative markets for assets that are illiquid or whose price cannot be observed directly. Cryptocurrency markets later built the instrument under a different funding rule.
Gupta A, Polson NG.
europepmc   +2 more sources

Shiller, Robert J. (Born 1946) [PDF]

open access: yes, 2014
Contains fulltext : 131879.pdf (Publisher’s version ) (Open Access)
Esther-Mirjam Sent
exaly   +2 more sources

The excess volatility puzzle explained by financial noise amplification from endogenous feedbacks. [PDF]

open access: yesSci Rep, 2022
The arguably most important paradox of financial economics—the excess volatility puzzle—first identified by Robert Shiller in 1981 states that asset prices fluctuate much more than information about their fundamental value.
Wehrli A, Sornette D.
europepmc   +2 more sources

Clinical perspectives on the value of testing for STK11 and KEAP1 mutations in advanced NSCLC. [PDF]

open access: yesFront Oncol
Standard first-line therapy for patients with metastatic non-small cell lung cancer (mNSCLC) without identified actionable mutations consists of regimens comprising immune checkpoint inhibitors (ICIs), alone or in combination with platinum-based ...
Shiller M, Johnson M, Auber R, Patel SP.
europepmc   +2 more sources

George A. Akerlof/Robert J. Shiller: Animal Spirits

open access: yesTér–Gazdaság–Ember, 2013
Das 2009 erschienene Werk stellt den Versuch dar, die moderne Makrookonomie, die weitestgehend durch die Neoklassik und das Modell rationaler Akteure bestimmt ist, auf behavioristischer und postkeynesianistischer Grundlage neu zu schreiben bzw. in wesentlichen Punkten zu erganzen.
Norbert Kovács
openaire   +3 more sources

Robert J. Shiller, Narrative Economics: How Stories Go Viral & Drive Major Economic Events

open access: yesOEconomia, 2021
The concept of ‘narratives’ is one of the ‘animal spirits’ in the 2009 book that Robert Schiller co-authored with another Nobel laureate, George Akerlof (Akerlof and Shiller, 2009). Since then, Shiller has developed the program of a ‘narrative economics’, with milestones such as the 2017 American Economic Association address (Shiller, 2017).
Carsten Herrmann-Pillath
openaire   +3 more sources

Empirical Asset Pricing: Eugene Fama, Lars Peter Hansen, and Robert Shiller [PDF]

open access: yesScandinavian Journal of Economics, 2014
AbstractThe Nobel Memorial Prize in Economic Sciences for 2013 was awarded to Eugene Fama, Lars Peter Hansen, and Robert Shiller for their contributions to the empirical study of asset pricing. Some observers have found it hard to understand the common elements of the laureates' research, preferring to highlight areas of disagreement among them.
John Y Campbell
exaly   +2 more sources

Population Genome Sequencing of the Scab Fungal Species Venturia inaequalis, Venturia pirina, Venturia aucupariae and Venturia asperata. [PDF]

open access: yesG3 (Bethesda), 2019
The Venturia genus comprises fungal species that are pathogens on Rosaceae host plants, including V. inaequalis and V. asperata on apple, V. aucupariae on sorbus and V. pirina on pear. Although the genetic structure of V.
Le Cam B   +15 more
europepmc   +2 more sources

Tumor diagnosis recharacterization enabled by comprehensive genomic profiling to guide precision medicine strategy. [PDF]

open access: yesNPJ Precis Oncol
Comprehensive genomic profiling (CGP) via next-generation sequencing is standard clinical practice for advanced and metastatic cancers in the U.S. and can help identify clinically actionable alterations in patients who may benefit from targeted therapies.
Carr A   +6 more
europepmc   +2 more sources

Home - About - Disclaimer - Privacy